In particular, CD34 is reduced in breast cancer 4 and prostate cancer 5 after neoadjuvant treatment and is usually related to VEGF expression, which negatively correlates to the response to neoadjuvant therapy in esophageal cancer tissue 6. The gene discussed is CD34; the disease is esophageal cancer.